MA55082A - Compositions, procédés, et kits pour l'administration de polyribonucléotides - Google Patents

Compositions, procédés, et kits pour l'administration de polyribonucléotides

Info

Publication number
MA55082A
MA55082A MA055082A MA55082A MA55082A MA 55082 A MA55082 A MA 55082A MA 055082 A MA055082 A MA 055082A MA 55082 A MA55082 A MA 55082A MA 55082 A MA55082 A MA 55082A
Authority
MA
Morocco
Prior art keywords
polyribonucleotides
kits
administration
compositions
methods
Prior art date
Application number
MA055082A
Other languages
English (en)
Inventor
Ellese Marie Carmona
Boer Alexandra Sophie De
Roger Joseph Hajjar
Avak Kahvejian
Nicholas Mccartney Plugis
Morag Helen Stewart
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA55082A publication Critical patent/MA55082A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055082A 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides MA55082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962812763P 2019-03-01 2019-03-01

Publications (1)

Publication Number Publication Date
MA55082A true MA55082A (fr) 2022-01-05

Family

ID=70005812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055082A MA55082A (fr) 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides

Country Status (10)

Country Link
US (1) US20220088049A1 (fr)
EP (1) EP3930683A1 (fr)
JP (2) JP7526195B2 (fr)
KR (1) KR20210134716A (fr)
CN (1) CN113543770A (fr)
AU (1) AU2020231349B2 (fr)
CA (1) CA3128615A1 (fr)
IL (1) IL285923A (fr)
MA (1) MA55082A (fr)
WO (1) WO2020180751A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51155A (fr) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
EP3946466A2 (fr) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées
EP4153152A1 (fr) * 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production d'anticorps polyclonaux humains
EP4464783A3 (fr) 2021-09-17 2025-01-22 Flagship Pioneering Innovations VI, LLC Compositions et procédés de production de polyribonucléotides circulaires
WO2023096990A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
KR20240125931A (ko) 2021-11-24 2024-08-20 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 수두-대상포진 바이러스 면역원 조성물 및 이의 용도
US20250032604A1 (en) 2021-11-24 2025-01-30 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023115013A1 (fr) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Procédés d'enrichissement en arn circulaire dans des conditions de dénaturation
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
WO2024192422A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
JP2026509462A (ja) 2023-03-15 2026-03-19 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー ポリリボヌクレオチドを含む組成物及びその使用
WO2025006684A1 (fr) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2025240369A2 (fr) * 2024-05-13 2025-11-20 Helix Nanotechnologies Inc Procédés de distribution de polyribonucléotides nus

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
US4283393A (en) * 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン,インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
JPH0558866A (ja) * 1991-08-28 1993-03-09 Lion Corp 口腔用組成物
ATE148889T1 (de) 1991-09-18 1997-02-15 Affymax Tech Nv Verfahren zur synthese der verschiedenen sammlungen von oligomeren
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
JPH07502898A (ja) 1992-01-13 1995-03-30 デューク・ユニバーシティー 酵素rna分子
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
ES2174075T3 (es) 1995-06-21 2002-11-01 Martek Biosciences Corp Librerias combinatorias de compuestos bioquimicos marcados y metodos para producir las mismas.
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
KR101033097B1 (ko) 2002-05-07 2011-05-06 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 표적 기관지내 요법을 위한 방법, 장치 및 제제
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
CN101060864A (zh) * 2004-09-21 2007-10-24 阿尼西瓦股份有限公司 多核苷酸的递送
EP1799271A4 (fr) * 2004-09-21 2010-05-05 Anesiva Inc Administration de polynucléotides
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 1本鎖環状rnaおよびその製造方法
JP5524189B2 (ja) 2008-06-06 2014-06-18 クォーク ファーマシューティカルズ インコーポレーティッド 耳障害治療のための組成物および方法
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
WO2011127255A1 (fr) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Préparation de nanoparticules de lipide
AU2011267078B2 (en) 2010-06-14 2014-09-25 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
RS63367B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
KR101938548B1 (ko) 2011-06-23 2019-01-15 (주)아모레퍼시픽 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물
ES2861428T3 (es) 2011-07-06 2021-10-06 Glaxosmithkline Biologicals Sa Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN
EP2765982A1 (fr) * 2011-10-11 2014-08-20 Hans Kosak Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques
RU2649364C2 (ru) * 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2016036735A1 (fr) 2014-09-05 2016-03-10 The Johns Hopkins University Particules pénétrant à travers le mucus, à base de liposomes, pour une administration par voie muqueuse
EP3256585A4 (fr) 2015-02-13 2018-08-15 Factor Bioscience Inc. Produits d'acides nucléiques et leurs procédés d'administration
ES2910425T3 (es) * 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
CN105664239B (zh) * 2016-03-23 2018-08-07 成都交大麦迪克科技有限公司 一种自粘附皮肤修复水凝胶的制备方法
CA3028682A1 (fr) * 2016-06-20 2017-12-28 Howard Y. Chang Arn circulaires et leur utilisation dans l'immunomodulation
RU2019121992A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Способы и композиции для доставки полезной нагрузки в виде нуклеиновых кислот и белков
JP7209951B2 (ja) 2017-10-30 2023-01-23 日本メナード化粧品株式会社 白髪予防及び改善剤

Also Published As

Publication number Publication date
CN113543770A (zh) 2021-10-22
EP3930683A1 (fr) 2022-01-05
KR20210134716A (ko) 2021-11-10
JP2024147750A (ja) 2024-10-16
IL285923A (en) 2021-10-31
JP2022523222A (ja) 2022-04-21
AU2020231349A1 (en) 2021-09-23
US20220088049A1 (en) 2022-03-24
WO2020180751A1 (fr) 2020-09-10
AU2020231349B2 (en) 2025-10-23
CA3128615A1 (fr) 2020-09-10
JP7526195B2 (ja) 2024-07-31

Similar Documents

Publication Publication Date Title
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3894343A4 (fr) Procédés et compositions pour l'administration de dioxyde de carbone
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP3938528A4 (fr) Procédés et compositions pour le diagnostique de la dépression
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP4009778A4 (fr) Procédés et compositions pour la production de mycéliums ectomycorhiziens et leurs procédés d'utilisation
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP3856742A4 (fr) Inhibiteurs de janus kinase 1 tricycliques, et compositions et procédés associés
EP3793562A4 (fr) Procédés et compositions pour inhiber la dihydroorotate déshydrogénase
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
EP3915262A4 (fr) Encodeur, décodeur et procédés correspondants pour l'interprédiction
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules
EP3853352A4 (fr) Plaque de puits fonctionnalisée, procédés de préparation et d'utilisation de celle-ci
EP3432872A4 (fr) Compositions et méthodes pour l'utilisation d'éflornithine et de dérivés et analogues de cette dernière pour le traitement de cancers, dont les gliomes
EP4058062A4 (fr) Compositions et méthodes pour l'immunothérapie
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
EP3814429A4 (fr) Compositions d'asphalte et procédés pour les former
EP3994214A4 (fr) Procédés d'accélération du durcissement de compositions de silicone
EP3950864A4 (fr) Composition d'apprêt
EP3314001A4 (fr) Procédés et compositions pour la préparation d'éphédrine et de composés alcaloïdes apparentés
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés